Non-cutaneous toxicity of targeted therapy for melanoma

Cutaneous melanoma accounts for most of deathsrelated to skin cancer. BRAF and MEK inhibitors are practice-changing drugs with overall response rates of up to 70% and median overall survival reaching 33 months. The majority of patients develops at least one adverse event (AE) during therapy; however, most AEs can be well managed and do not require treatment discontinuation.

Around 40% of cutaneous melanomas harbor a BRAF^V600 mutation, which can be targeted with BRAF and MEK inhibitors (BRAFi and MEKi).¹ First introduced to the market in 2011, currently there are three combinations of BRAFi and MEKi: vemurafenib (V) and cobimetinib (C), dabrafenib (D) and trametinib (T), and encorafenib (E) and binimetinib (B).